Trofosfamide

Chemical compound
  • L01AA07 (WHO)
Legal statusLegal status
  • DE: § 48 AMG/§ 1 MPAV (Prescription only)
Identifiers
  • N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide 2-oxide
CAS Number
  • 22089-22-1 checkY
PubChem CID
  • 65702
ChemSpider
  • 59129 ☒N
UNII
  • H64JRU6GJ0
KEGG
  • D07252 checkY
ChEMBL
  • ChEMBL462019 ☒N
CompTox Dashboard (EPA)
  • DTXSID60865031 Edit this at Wikidata
ECHA InfoCard100.040.686 Edit this at WikidataChemical and physical dataFormulaC9H18Cl3N2O2PMolar mass323.58 g·mol−13D model (JSmol)
  • Interactive image
  • C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
InChI
  • InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2 ☒N
  • Key:UMKFEPPTGMDVMI-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue,[clarification needed] supratentorial PNET, and recurrent brain tumors.[2]

References

  1. ^ Jahnke K, Thiel E, Bechrakis NE, et al. (December 2008). "Ifosfamide or trofosfamide in patients with intraocular lymphoma". J. Neurooncol. 93 (2): 213–7. doi:10.1007/s11060-008-9761-8. PMID 19099202. S2CID 33892177.
  2. ^ "Trofosfamide". www.drugbank.ca. Retrieved 2019-12-19.
  • v
  • t
  • e
SPs/MIs
(M phase)
Block microtubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDTOther
Enzyme inhibitors
Receptor antagonists
Other/ungrouped
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e